Stock Analysis on Net
Stock Analysis on Net

Abiomed Inc. (NASDAQ:ABMD)

This company has been moved to the archive! The financial data has not been updated since November 3, 2022.

Income Statement
Quarterly Data

The income statement presents information on the financial results of a company business activities over a period of time. The income statement communicates how much revenue the company generated during a period and what cost it incurred in connection with generating that revenue.

Abiomed Inc., consolidated income statement (quarterly data)

US$ in thousands

Microsoft Excel
3 months ended: Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016
Revenue 265,921 277,149 269,850 261,176 248,142 252,585 241,245 231,663 209,764 164,850 206,659 221,584 204,974 207,666 207,081 200,563 181,778 180,010 174,436 154,022 132,823 132,468 124,680 114,674 102,955 102,995
Cost of revenue (48,880) (52,626) (51,457) (47,627) (43,886) (45,188) (46,078) (41,110) (38,736) (35,983) (39,369) (39,996) (34,867) (37,073) (34,848) (34,023) (29,846) (30,850) (30,098) (24,994) (21,627) (21,862) (19,261) (18,987) (17,309) (15,070)
Gross profit 217,041 224,523 218,393 213,549 204,256 207,397 195,167 190,553 171,028 128,867 167,290 181,588 170,107 170,593 172,233 166,540 151,932 149,160 144,338 129,028 111,196 110,606 105,419 95,687 85,646 87,925
Research and development (42,089) (40,477) (43,785) (40,869) (41,041) (37,708) (31,989) (33,004) (30,525) (26,357) (25,345) (25,655) (23,969) (23,790) (25,548) (23,965) (22,717) (21,273) (21,270) (17,706) (19,390) (16,931) (16,325) (16,349) (18,052) (15,660)
Selling, general and administrative (116,958) (117,996) (109,605) (107,618) (102,779) (103,484) (100,374) (86,198) (79,167) (68,444) (83,892) (85,674) (85,956) (86,078) (81,296) (80,220) (78,895) (81,139) (75,501) (66,556) (60,080) (60,597) (60,100) (53,935) (53,086) (51,032)
Acquired in-process research and development — — — (496) — (115,490) — — — — — — — — — — — — — — — — — — — —
Income (loss) from operations 57,994 66,050 65,003 64,566 60,436 (49,285) 62,804 71,351 61,336 34,066 58,053 70,259 60,182 60,725 65,389 62,355 50,320 46,748 47,567 44,766 31,726 33,078 28,994 25,403 14,508 21,233
Interest and other income (expense), net 80,709 3,772 9,759 (6,689) 6,835 39,935 10,690 9,384 11,579 27,010 (18,740) 26,757 (42,824) 42,413 33,141 2,155 1,513 1,739 940 888 758 714 362 423 228 192
Income (loss) before income taxes 138,703 69,822 74,762 57,877 67,271 (9,350) 73,494 80,735 72,915 61,076 39,313 97,016 17,358 103,138 98,530 64,510 51,833 48,487 48,507 45,654 32,484 33,792 29,356 25,826 14,736 21,425
Income tax (provision) benefit (32,570) (15,268) (14,437) (12,125) (10,318) (17,175) (16,638) (18,867) (10,702) (16,488) (7,515) (27,799) (4,287) (14,215) (24,569) (19,648) (1,706) 41,579 (11,660) (32,208) (7,981) 3,582 (14,457) (10,394) (5,861) (8,515)
Net income (loss) 106,133 54,554 60,325 45,752 56,953 (26,525) 56,856 61,868 62,213 44,588 31,798 69,217 13,071 88,923 73,961 44,862 50,127 90,066 36,847 13,446 24,503 37,374 14,899 15,432 8,875 12,910

Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-K (reporting date: 2022-03-31), 10-Q (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-K (reporting date: 2021-03-31), 10-Q (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-K (reporting date: 2020-03-31), 10-Q (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-K (reporting date: 2019-03-31), 10-Q (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-K (reporting date: 2018-03-31), 10-Q (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-K (reporting date: 2017-03-31), 10-Q (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30).

Income statement item Description The company
Revenue Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. Abiomed Inc. revenue increased from Q4 2022 to Q1 2023 but then decreased significantly from Q1 2023 to Q2 2023.
Income (loss) from operations The net result for the period of deducting operating expenses from operating revenues. Abiomed Inc. income (loss) from operations increased from Q4 2022 to Q1 2023 but then decreased significantly from Q1 2023 to Q2 2023.
Income (loss) before income taxes Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Abiomed Inc. income (loss) before income taxes decreased from Q4 2022 to Q1 2023 but then increased from Q1 2023 to Q2 2023 exceeding Q4 2022 level.
Net income (loss) The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Abiomed Inc. net income (loss) decreased from Q4 2022 to Q1 2023 but then increased from Q1 2023 to Q2 2023 exceeding Q4 2022 level.